Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V 3526

Drug Profile

V 3526

Alternative Names: V3526; VEE 3526; VEE IA/B V3526; VEE Vaccine; Venezuelan equine encephalitis virus vaccine - DynPort

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator United States Army Medical Research Institute of Infectious Diseases; University of North Carolina at Chapel Hill
  • Developer Charles River Laboratories; DynPort Vaccine Company
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Venezuelan equine encephalomyelitis

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for preclinical development in Venezuelan-equine-encephalomyelitis in USA (SC, Injection)
  • 09 Feb 2017 Preclinical development is ongoing in USA (NCT03051386)
  • 09 Feb 2017 US Army Medical Research and Materiel Command plans a phase II trial for Encephalomyelitis (Prevention) (In Volunteers) in USA (NCT03051386)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top